Inotuzumab ozogamicin following allogeneic hematopoietic stem cell transplantation successfully rescued relapse of CD19-negative acute lymphoblastic leukemia after CAR-T cell therapy

Pediatr Blood Cancer. 2021 May;68(5):e28980. doi: 10.1002/pbc.28980. Epub 2021 Feb 22.

Authors

Affiliations

¹ Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
² Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
³ Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

PMID: 33619887
DOI: 10.1002/pbc.28980

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / therapeutic use*
Child
Hematopoietic Stem Cell Transplantation / methods
Humans
Immunotherapy, Adoptive
Inotuzumab Ozogamicin / therapeutic use*
Male
Neoplasm Recurrence, Local / drug therapy*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy*
Receptors, Chimeric Antigen
Salvage Therapy / methods*
Transplantation, Homologous

Substances

Antineoplastic Agents, Immunological
Receptors, Chimeric Antigen
Inotuzumab Ozogamicin